Biolinq has created a revolutionary biowearable experience using an array of ultra-small electrochemical sensors for metabolic health monitoring. Their flagship product, Biolinq Shine2, is the first fully autonomous, needle-free glucose sensor that integrates glucose, activity, and sleep tracking in a single device. This device provides a simple user experience with real-time insights to support healthier decisions by constantly monitoring glucose levels with color-changing LED indicators, alongside physical activity and sleep patterns.

The company is dedicated to bringing biosensing and biowearables mainstream over the next decade. They emphasize continuous sensing applications with multiple analytes such as glucose, ketones, and lactate, all aimed at delivering actionable metabolic health insights. Biolinq also prioritizes the personal and professional growth of its team members and fosters a positive and creative work environment.

Biolinq's technology integrates a continuous intradermal glucose sensor with a color-changing indicator light and multiple microsensors, including an accelerometer and ambient light sensor. The sensor is designed to aid in managing glycemic control for persons 22 years or older who are not on insulin. The accompanying app provides more detailed glucose data correlated with meals, rest, and activity to help users make acute behavior and lifestyle modifications. The company is committed to innovation in medical biosensing and improving metabolic health for millions of people worldwide.